Phase I study (reformulated) Fitzgerald K, et al. 2014.
read more »
LIB003 is a recombinant fusion drug which combines a PCSK9-binding domain (adnectin) with human serum albumin. LIB003 is given as a monthly subcutaneous injection.read more »
Alirocumab is being evaluated in the ODYSSEY clinical trial programme including studies in patients with familial hypercholesterolaemia (FH), and patients with hypercholesterolaemia, including those at high cardiovascular risk.read more »
Evolocumab has been evaluated in the PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations) clinical trial programme.read more »
Bococizumab: SPIRE clinical trial programme (terminated).read more »